Ramesh Swaminathan, Global CFO of pharmaceutical company Lupin, warns that Trump tariffs could deny many in the U.S. access ...

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising ...

Lupin has received tentative approval from the Food and Drug Administration for darunavir, cobicistat, emtricitabine, and ...

I’ve had so much luck using lupin flour. I use this incredible almost zero-carb flour... The post Lupin Flour Pizza Crust ...

Lupin transfers OTC business to subsidiary for Rs ₹550-650 crore, reports strong Q3 financial performance with profit and ...

Aside from reciprocal tariffs, US President Trump has teased imposing tariffs on several import heavy sectors, including ...

Lupin shares saw a strong recovery on February 12 after the company reported solid Q3 FY25 earnings. The stock, which ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

KR Choksey is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2472 in its research report dated February 13, 2025.

The company reported a profit after tax of ₹8,589 crore, a 38.8% increase from the previous year's ₹6,187 crore. Its total ...

Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or ...

The share price of Lupin Ltd. fell over 3% on Wednesday despite a 39.5% jump in its net profit for the quarter ended December. The decline comes as Nifty fell below 23,000 support level. In addition, ...